High unmet-need infectious disease opportunities.
Despite advances in pharmaceutical science, considerable unmet medical needs exist in the field of anti-infective therapies. While pharmaceutical companies have focused research efforts on a few selected areas of the field, new microbial diseases have steadily increased in prevalence. Three emerging areas in the field of anti-infectives now represent large commercial opportunities: Gram-negative infections, community-acquired methicillin-resistant Staphylococcus aureus, and Clostridium difficile-associated diarrhea. Dedication and extensive investment by pharmaceutical companies is required to battle against these emerging and deadly microbial infections.
Tipirneni
Praveen
P
Cubist Pharmaceuticals Inc, 65 Hayden Avenue, Lexington, MA 02421, USA. praveen.tipirneni@cubist.com
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D016360:Clostridioides difficile; D017714:Community-Acquired Infections / Q000188:drug therapy; D015195:Drug Design; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy; D006801:Humans; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents